Our latest thinking on the key strategic questions facing device and biopharma executives in hearing healthcare.
With hearing loss considered to be a social determinant of health, Medicare Advantage payers have taken a more comprehensive approach to hearing healthcare over the last five years.
Once the FDA finalizes guidelines, the six global hearing aid companies will face a trajectory familiar to other sectors that have shifted to OTC in the past.
An important trend contributing to the consumerization of healthcare is the transformation of select prescription categories to over-the-counter.
The recent AAA 2018 convention in Nashville offered some examples of how the worlds of consumer listening devices and hearing aid technology are colliding.
The impact of stigma looms large, and incorporating stigma counseling into audiology practices is beneficial to patients and clinicians.
My recommendation: audiologists should conduct market tests now to start formulating their product and service strategies for when the Over-the-Counter (OTC) regulations take effect.
Hearing companies are advancing towards the starting blocks for what’s shaping up to be a new race to solve hearing loss. Before sprinting ahead, they need to assess the role of patient engagement in their go-to-market strategies.
Is today’s hearing health care caught up with the specific needs of hearing-impaired and physically active patients?
Audiologists have a window of opportunity, before over-the-counter (OTC) hearing aids hit the market, to add value to their patient offering and differentiate their practices.
The FDA rocked the hearing-health world on December 7, 2016 by announcing its intent to consider a class of OTC hearing aids.